🏛️ Verified NIH Record • Updated 2026-08-27
A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (NCT04606381)
An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Amivantamab, a Human Bispecific EGFR and cMet Antibody for the Treatment of Advanced Solid Malignancies
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Janssen Research & Development, LLC
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess the feasibility of subcutaneous (SC) administration of amivantamab based on safety and pharmacokinetics and determine a dose, dose regimen and formulation for amivantamab SC delivery.
Who can join: Review the eligibility criteria below.
Location: Cedars Sinai Medical Center — West Hollywood, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (12 Sites)
- Cedars Sinai Medical Center — West Hollywood, California
- Community Health Network — Indianapolis, Indiana
- Langone Health at NYC University, NYU School of Medicine — New York, New York
- Providence Portland Medical Center — Portland, Oregon
- Sarah Cannon Research Institute — Nashville, Tennessee
- University Health Network — Toronto, Ontario
- Chungbuk National University Hospital — Cheongju-si,
- Seoul National University Bundang Hospital — Seongnam-si,
- Severance Hospital Yonsei University Health System — Seoul,
- Samsung Medical Center — Seoul,
- The Christie Nhs Foundation Trust — Manchester,
- Royal Marsden Hospital — Sutton,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Neoplasms
- A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers — St Louis, Missouri
- A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) — Goodyear, Arizona
- Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors — Birmingham, Alabama
- Hispanic Adapted and Culturally Relevant Exercising Together — Tucson, Arizona
- M7824 Related Adverse Effects in Adults With Cancer — Bethesda, Maryland
- Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors — Duarte, California
Explore by condition: All Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.